FDA Accepts PaxVax, Inc.’s IND for Single-Dose Oral Cholera Vaccine  
3/19/2012 6:28:44 AM

MENLO PARK, Calif.--(BUSINESS WIRE)--PaxVax Corporation, developer of innovative and socially responsible oral vaccines against infectious diseases, announced that the U.S. Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application for its single-dose oral cholera vaccine, clearing the way to begin clinical trials. The company intends to begin Phase 3 trials later this year.